EGFR GENE MUTATION
Clinical trials for EGFR GENE MUTATION explained in plain language.
Never miss a new study
Get alerted when new EGFR GENE MUTATION trials appear
Sign up with your email to follow new studies for EGFR GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo shrinks lung tumors before surgery in early trial
Disease control OngoingThis study tests a two-step treatment for people with a specific type of lung cancer (EGFR-mutant, stage II-IIIB). First, patients take a targeted pill (almonertinib), then receive a combination of immunotherapy (adebrelimab) and chemotherapy. After these treatments, they have su…
Matched conditions: EGFR GENE MUTATION
Phase: PHASE2 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Lung cancer combo shows promise in slowing tumor growth
Disease control OngoingThis phase 2 trial tests whether adding ramucirumab to the standard drug osimertinib helps people with advanced EGFR-mutant lung cancer live longer without their disease worsening. About 160 patients will receive either the combination or osimertinib alone. The study aims to see …
Matched conditions: EGFR GENE MUTATION
Phase: PHASE2 • Sponsor: Xiuning Le • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New combo aims to fight lung cancer without chemo
Disease control OngoingThis early-phase trial tests whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for patients with stage II or III non-small cell lung cancer that cannot be surgically removed. The study enrolls 21 participants who hav…
Matched conditions: EGFR GENE MUTATION
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests the safety and best dose of the drug neratinib when combined with one of three other drugs (everolimus, palbociclib, or trametinib) in people with advanced solid tumors that have certain gene mutations or amplifications. The study enrolls 93 participa…
Matched conditions: EGFR GENE MUTATION
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New combo therapy aims to outsmart tough lung cancer mutations
Disease control OngoingThis phase 3 trial compares the standard drug osimertinib alone versus osimertinib combined with two chemotherapy drugs (carboplatin and pemetrexed) as a first treatment for people with advanced non-squamous lung cancer that has both EGFR and TP53 mutations. The study involves 29…
Matched conditions: EGFR GENE MUTATION
Phase: PHASE3 • Sponsor: Li Zhang, MD • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Smartwatch and app aim to track lung cancer symptoms in real time
Knowledge-focused OngoingThis study tests whether a remote monitoring system—including a smartphone app, a Fitbit, and a smart pill cap—can effectively track symptoms and side effects in 30 lung cancer patients taking oral targeted therapy. Participants will use the system for up to 24 weeks, and the goa…
Matched conditions: EGFR GENE MUTATION
Phase: NA • Sponsor: University of Virginia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC